14 November 2011
New Preclinical Data Demonstrates the Utility of PG545 in Ovarian Cancer at AACR/NCI/EORTC Cancer Conference
31 October 2011
Notice of Annual General Meeting
30 September 2011
Director Resignation
30 September 2011
Annual Report to Shareholders
27 September 2011
Progen Licensee Commences Recruitment; Completion of Settlement Agreement
20 September 2011
Closure of PG545 Phase 1a Clinial Trial
29 June 2011
PI-88 Receives Orphan Medicinal Product Designation
23 June 2011
PI-88 Phase III Update
21 June 2011
Appendix 3X - Woei-Jia Jiang
21 June 2011
Appendix 3Z - Paul Lin
16 June 2011
Progen Board and Senior Management Changes
19 May 2011
Progen Completes Epi Pharmaceuticals Inc. Formation and Reduces Company Risk
16 May 2011
Diversity Policy
19 April 2011
Progen Licensee Gains Approval for Phase III Clinical Trial
6 April 2011
Progen's PG11047 Clinical Study Completes Enrolment
5 April 2011
Progen Presents New Preclinical Data at AACR Annual Meeting
30 March 2011
Progen Enters Diabetes Collaboration with ANU
29 March 2011
Wholesale Investor Company Presentation
23 March 2011
Company Newsletter
23 February 2011
Boardroom Radio Australia Interviews CEO Sue MacLeman
16 February 2011
Progen Release Half-Yearly Report And Accounts
3 Februaury 2011
Progen's PG545 Positive Anti-Cancer Data Published In British Journal Of Cancer
25 January 2011
Progen Granted US Patent
31 December 2010
Progen Securities Trading Policy
16 November 2010
2010 AGM Notice Of Meeting
16 November 2010
Chairmans Address - 2010 AGM
16 November 2010
2010 Annual General Meeting - Results of Meeting
16 November 2010
AGM Presentation 2010
15 November 2010
Progen's PG545 To Enter Clinic In First In-Human Cancer Trials
12 November 2010
Progen Receives Purchase Order For PI-88 Clinical Trial Material
29 October 2010
Progen Closes US Office And Continues To Drive Strategy To Rebuild Business And Reduce Costs
19 October 2010
Progen Presents At Australasian Life Science Investment Summit
12 October 2010
Progen Presents PG545 at TRX10 Conference
30 September 2010
Annual Report To Shareholders
15 September 2010
Progen Pharmaceuticals' Rodman & Renshaw webcast available from 11:15am EDT for 90 days
15 September 2010
Progen Presents at Rodman & Renshaw Investor Conference
14 September 2010
Publication on PG11047
01 September 2010
Progen Pharmaceuticals Licensee Submits Updated SPA to FDA
02 July 2010
Progen Nasdaq Delisting Update
30 June 2010
Preliminary Final Report 2010
28 June 2010
Progen Granted Muparfostat (PI-88) Patent in Japan
30 June 2010
Progen Pharmaceuticals Ltd signs Licence and Collaboration Agreement with Medigen Biotech Corp
24 June 2010
Progen Receives Delisting Notification from Nasdaq
31 May 2010
Company Newsletter
28 May 2010
Expiry of Options
27 May 2010
Progen Subsidiary Secures Manufacturing Contract
24 May 2010
Company Secretary Resignation
19 May 2010
Progen Pharmaceuticals Ltd Granted Muparfostat (PI-88) Patent in Europe
30 April 2010
Progen and Medugen Sign Non-Binding Letter of Intent
20 April 2010
Progen Subsidiary Secures Manufacturing Contract
08 April 2010
Progen Appoints Directors to Wholly-Owned Subsidiary
29 March 2010
Progen Appoints New Chief Executive Officer
16 March 2010
Progens Roadshow Presentation
01 March 2010
Company Secretary Appointment
26 February 2010
Half Yearly Report and Accounts